Speaker Profile

Ph.D., CEO, Genialis Inc.

Biography
Rafael leads Genialis company’s effort to model patient biology to realize the promise of precision medicine and therapeutic discovery. He spent nearly 20 years in biomedical research prior to Genialis, publishing on the evolution of innate immune systems, bioengineering of microbes, and genetics of development. He has also nurtured a specialty in developing software for high-throughput molecular design and analyses, co-inventing the j5 DNA assembly design automation tool (which has since been commercialized by TeselaGen Biotechnology). Rafael attended Dartmouth College and then Yale University, where he was an NSF Graduate Research Fellow. He went on to postdoctoral training in Jay Keasling’s synthetic biology group at Lawrence Berkeley National Laboratory, Joint BioEnergy Institute (JBEI), followed by a National Library of Medicine Keck fellowship in Biomedical Informatics at Baylor College of Medicine. In his free time, Rafael enjoys cooking and rock climbing, and raising heirloom tomatoes and two precocious children.


AI and Data Science Showcase:
Genialis, Inc.

Genialis is a computational precision medicines company unravelling complex biology to find new ways to address disease. ResponderID™, Genialis’ clinical biomarker discovery platform, defines, models, and validates actionable biomarkers and optimally positions novel drugs to accelerate translational research and clinical development.

Machine-Learning for Clinical Biomarker Discovery
The research space churns out biomarkers while the clinical space struggles to deliver them for patient reporting. I will discuss biomarker development challenges and describe ML-enabled and ML-enabling solutions Genialis uncovered on the road to validating a clinical assay.

 Session Abstract – PMWC 2022 Silicon Valley

Track 6, June 28-30


The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative